The National Medical Products Administration (NMPA) has approved the application of pyrotinib combined with capecitabine in HER2-positive advanced breast cancer, but pyrotinib has not yet been for advanced nonsmall cell lung cancer. Here, ERBB2 is linked to breast cancer.